Congratulations!
Welcome to Personal Finance

 

Dear Reader,

I’m Joe Duarte, M.D., and I want to thank you for viewing my presentation today.

In addition, I want to say “Congratulations” on your decision to join Personal Finance.

As I explained in my presentation, technology has likely created more millionaires and billionaires than any other sector in history.

It’s also generated trades like Amgen that turned every $1,000 into $1.78 million in a relatively short time span.

But the money about to be made on this cancer vaccine breakthrough could DWARF it all.

Cancer currently generates $91 billion every year for chemo, radiation, and surgery. And that number is projected to nearly double.

But if results from clinical trials at institutions like Stanford, Duke, and John Hopkins are even half-right… this cancer vaccine will make current cancer care OBSOLETE the second it hits the market.

The tiny company that owns all the patents on this development trades for a fraction of what my models are predicting.

If it grabs just a percentage of the money spent on kidney cancer treatment alone – and it’s poised to take a whole lot more – it could trade for well over $136.

We’re talking about potential gains of up to 2,700%.

Because this cancer breakthrough is so vital for so many lives…

The FDA has already granted this treatment a rare legal designation that virtually guarantees approval.

Six countries worldwide – including England and Germany – have already approved it… and it’s right now entering hospitals around the world.

When the final phase of clinical trials ends, the FDA is set to quickly follow their lead – unleashing the first wave of massive profits.

Investors who buy in now could see the biggest windfall of their lives…

All while helping support a vital life-saving treatment for 14 million cancer sufferers.

To help you get in on the ground floor quickly, I’ve put together a resource package detailing everything you need to know about this incredibly lucrative and urgent medical opportunity.

Just take a look at everything you get today:

One Little Shot to Kill Cancer Dead:
27 Times Your Money on the “Alpha Cells” Discovery

This briefing contains not one, not two, but three explosive opportunities:

• "Alpha Cells" Play #1: Breakthrough medical technology sparks new cancer biotech revolution!
  If you could only own one cancer therapy company for the next 10 years, this would be the one. This company has been on the cutting edge of the “Alpha Cells” discovery from the very beginning. Its founders even include the scientist who discovered and won the Nobel Prize for his cancer breakthrough. Already, scientists at Duke, John Hopkins, Stanford, and UCLA have testified to its cancer-killing power. Again and again, over 1,065 independent studies have confirmed that its “cancer vaccine” can destroy just about any type of cancer – without dangerous side effects. That’s why the FDA passed a special legal ruling for this company’s “Alpha Cells” treatment... one that’s helped it sail through clinical trials right to the FDA’s doorstep. Other companies that have received this special ruling, like Amgen, have surged for 178,800% gains. And this opportunity could be no different. When its final phase of trials reaches its close, a critical announcement could send shares surging overnight from $10... to $50... to $136. Good enough to turn every $10,000 into $270,000, and that’s just the beginning!

• "Alpha Cells" Play #2: This tiny company could be the target of a $10 billion buyout!
  This company is on the radar of every Big Pharma company scrambling for a major edge in the cancer immunotherapy market. Hedge-fund managers claim a buyout could amount to a staggering $10 billion... equal to over 7 times its market cap. Why would they pay so much? Its cutting-edge technology is now shaping up to be a major player in the CAR-T immunotherapy market. In essence, it genetically programs our immune system’s T-Cell warriors to directly attack cancer cells.The real kicker is its safety mechanism, which “turns off” T-Cells to avoid damage to healthy cells.It’s so impressive, in fact, that MD Anderson Cancer Center – the world’s leading cancer research hospital – has signed a deal to employ this technology. The president of the hospital even says it “represents one of the most exciting approaches with curative potential in oncology today.” With a stunning portfolio of patents, this company is an innovative leader light-years ahead of the competition. DO NOT WAIT for the coming buyout. By then, the stock could be sitting on gains as high as 542%. Get in now!

• "Alpha Cells" Play #3: Triple your money on the Big Pharma of immunotherapy. 
  My final play only recently IPO’d, but in a short time it’s become the Big Pharma of cancer immunotherapy. While it’s much bigger and trades for more than the first two plays I mentioned, there’s still TONS of upside.The results of one clinical trial on its therapy for leukemia boosted patient survival rate 9 times over! Results like these have Big Pharma scrambling to cut deals.One pharmaceutical giant recently inked a $1 billion licensing deal with this company – the largest upfront sum EVER for a biotech agreement. The deal alone values the shares at around $94, a 75% return on current value. What’s more, it’s got a war chest that almost every biotech startup would envy. That’s how it’s managed to grab large shares of the explosive immuno-oncology market – scooping up tinier companies patents and assets. A buyout for one or both of the first plays in this report is not out of the question. Based on the current value of assets and cash on hand – plus upcoming clinical trial dates – my research shows that this new “Big Pharma of immunotherapy” could triple your money.

Personal Finance has a 40-Year Track Record of Success

This investor briefing is only a small part of what you’ll get as a new member of Personal Finance.

You’ll also have access to all of these incredible advantages you won’t find anywhere else:

• 24 ISSUES PER YEAR – Each month we release two 12-page issues chock-full of comprehensive analysis of major market trends and emerging investment stories. That includes updates to both our Growth and Income portfolios.
• PERSONAL FINANCE FLASH ALERTS – Any time there’s breaking news on on of our positions, or a new opportunity comes along that just can’t wait, you’ll get a flash trade alert.
• 24/7 WEB RESOURCE ACCESS – Inside this password-protected website, you’ll get an easy-to-use collection of research. That includes every issue, flash alert, and Special Report we’ve ever put out.
• STOCK TALK MESSAGE BOARDS – This one is a subscriber favorite. Here’s something unique about Personal Finance. You can ask questions directly using our Stock Talk message boards. I enjoy answering your questions, and I’ll respond promptly.
• FIRST-CLASS CUSTOMER SERVICE – You can rest easy knowing that you’ll always have the support of our dedicated Customer Service staff. You won’t get a call center when you contact us. Our Customer Service staff is dedicated to our products – and they’ll do everything they can to make you happy.

Now, you’re probably wondering: How much is a resource like this worth?

Some industry insiders tell me that a full year of Personal Finance is easily worth $500. Some even feel $1,000 per year is more commensurate with the full value of Personal Finance.

But don’t worry, you’re not going to pay anywhere near that.

Normally, Personal Finance has a price of $99 per year. But for a limited time…

You can become a member for just $39.95
(A 60% savings!)

If you decide Personal Finance is right for you, then great!

For the next three months, you can secure a stake in the company I’ve told you about today, and every other opportunity we share with you.

You’ll be granted unrestricted access to all of our analysis, reports, and briefings — as well as the Personal Finance members’ website and portfolios.

Plus you can utilize the private stock discussion board available to you.

If for any reason during your first 90 days you feel this isn’t a good fit, simply contact me — or any member of my team — and I’ll quickly refund every penny of your subscription.

That’s how confident I am that Personal Finance can change your fortunes.

I think you’ll agree: That’s as fair as it gets.

Go ahead, dive in. Enjoy yourself. And pay very close attention to the urgent recommendation I’m making today.

 

And remember, even if you decide to cancel your subscription for a full refund, you keep everything you’ve received, including the special briefing.

You have absolutely nothing to lose! Please don’t miss out. Only 200 people today will get all this at an amazingly low price. So act now.

Sincerely,

Joe Duarte, M.D

If you prefer to order over the phone, our customer service team is available at (800) 832-2330